AKT-Vimentin interaction; a potential role in soft tissue sarcoma progression and
AKT-波形蛋白相互作用;
基本信息
- 批准号:8458614
- 负责人:
- 金额:$ 29.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2015-10-31
- 项目状态:已结题
- 来源:
- 关键词:AKT inhibitionAccountingAddressAdhesionsAffectAneuploidyApoptosisArchitectureAttentionAutomobile DrivingBackBehaviorBindingCarcinomaCell Cycle ArrestCell LineCell physiologyCellsChromosomal translocationClinicalComplexCytogeneticsDataDiseaseDistantEnvironmentEpithelialEtiologyFamilyGoalsGrowthHeterogeneityHistologyHumanHuman Cell LineImmigrationIn VitroInduction of ApoptosisIntermediate FilamentsInvestigationKaryotypeKnowledgeLaboratoriesLearningLungMalignant - descriptorMalignant Fibrous HistiocytomaMalignant NeoplasmsMesenchymalModelingMolecularMolecular ProfilingMusNeoplasm MetastasisOutcomePathway interactionsPatientsPhosphorylationPhosphotransferasesPreclinical TestingProcessPropertyProto-Oncogene Proteins c-aktRecurrenceRegulationResearchResistanceRoleSamplingSecondary toSignal PathwaySignal TransductionStructural ProteinTherapeuticTissuesTranslatingTumor MarkersUndifferentiatedVimentinXenograft ModelXenograft procedureabstractingbasecancer cellcell motilityepithelial to mesenchymal transitionfibrosarcomaimprovedin vivointerestleiomyosarcomamigrationmouse modelneoplastic cellnovelnovel therapeutic interventionoutcome forecastpre-clinicalprotein kinase C kinasesarcomasoft tissuestemtreatment centertumortumorigenic
项目摘要
Project Summary/Abstract
Soft tissue sarcomas (STS) constitute a family of mesenchymal -origin malignancies that
can occur anywhere in the body. Comprising more than 50 distinct histological subtypes,
STS share several distinctive features that include frequent local recurrence after
definitive therapy, marked chemoresistance, and frequent metastasis, especially to the
lungs. These features translate to a dismal outcome, especially for those patients
harboring high grade complex karyotype STS histologies, consisting mainly of
leiomyosarcoma and high grade pleomorphic sarcoma ( malignant fibrous histiocytoma
and fibrosarcoma). To improve STS therapeutic outcome it will be critical to develop
novel agents that capitalize on underlying STS points of molecular vulnerability;
however, progress towards this urgent goal are hampered by our minimal understanding
of the molecular determinants underlying STS prog ression and dissemination.
Tumor cells, including STS, respond to signaling cascades that control growth regulation
processes and other components of the malignant process such as motility, invasion,
induction of apoptosis, etc. Among theses signaling mechanisms, the AKT kinase
pathway may be particularly important in STS growth and dissemination.
Phosphorylation of AKT is a critical step in this cascade, had has been associated with
impaired STS prognosis when identified in STS tissues. In human STS cell lines and
human STS xenografts growing in immuno -incompetent mice, AKT inhibition interferes
with STS growth, perhaps by disrupting AKT interaction with vimentin, a critical
structural protein that may also have oncologically-relevant functional properties.
Our group is apparently the first to identify the existence of AKT -vimentin interactions.
We propose to study the regulation of this interaction, hoping to learn more about the
mechanisms underlying these interactions, the functional significance of this interaction
regarding how it impacts on STS proliferation and metastasis in vivo, and finally to test
preclinical therapeutic approaches to AKT and vimentin blockade, hoping to demonstrate
preclinical relevance using human STS xenograft mouse models and murine sarcoma
models.
项目摘要/摘要
软组织肉瘤(STS)构成了一个间充质 - 原家基因疾病的家族
可以发生在体内的任何地方。包括50多个不同的组织学亚型,
STS具有几个独特的功能,包括频繁的本地复发
确定的治疗,明显的化学耐药性和频繁的转移,特别是对
肺。这些功能转化为令人沮丧的结果,特别是对于那些患者
携带高级综合核型sts组织学,主要包括
平滑肌肉瘤和高级多形性肉瘤(恶性纤维组织细胞瘤
和纤维肉瘤)。为了改善STS治疗结果,开发至关重要
利用分子脆弱性的基本点的新型药物;
但是,我们最少的理解阻碍了这一紧急目标的进展
STS前进和传播的分子决定因素的。
肿瘤细胞,包括ST,对控制生长调节的信号级联反应
恶性过程的过程和其他组成部分,例如运动,入侵,
在这些信号传导机制中诱导凋亡等。
途径在STS的生长和传播中可能尤其重要。
AKT的磷酸化是该级联的关键步骤,与
在STS组织中鉴定出STS预后受损。在人类的细胞系中
人类STS异种移植物在免疫功能不足的小鼠中生长,AKT抑制作用会干扰
随着STS的增长,也许通过破坏与波形蛋白的AKT相互作用,这是一个关键
结构蛋白也可能具有与肿瘤学的功能特性。
我们的小组显然是第一个确定Akt -Vimentin相互作用的存在的人。
我们建议研究这种互动的调节,希望了解更多有关
这些相互作用的基础机制,这种相互作用的功能意义
关于它对体内STS增殖和转移的影响,最后测试
临床前治疗方法对AKT和波形蛋白封锁,希望证明
使用人类STS异种移植小鼠模型和鼠肉瘤的临床前相关性
型号。
项目成果
期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas.
- DOI:10.1016/j.scr.2013.04.011
- 发表时间:2013-09
- 期刊:
- 影响因子:1.2
- 作者:Zhang, Yan;Young, Eric D.;Bill, Katelynn;Belousov, Roman;Peng, Tingsheng;Lazar, Alexander J.;Pollock, Raphael E.;Simmons, Paul J.;Lev, Dina;Kolonin, Mikhail G.
- 通讯作者:Kolonin, Mikhail G.
The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study.
c-Met 通路成分在未分类的多形性肉瘤/恶性纤维组织细胞瘤 (UPS/MFH) 中的表达:组织微阵列研究。
- DOI:10.1111/j.1365-2559.2011.03946.x
- 发表时间:2011
- 期刊:
- 影响因子:6.4
- 作者:Lahat,Guy;Zhang,Pingyu;Zhu,Quan-Sheng;Torres,Keila;Ghadimi,Markus;Smith,KerringtonD;Wang,Wei-Lien;Lazar,AlexanderJ;Lev,Dina
- 通讯作者:Lev,Dina
Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.
- DOI:10.1371/journal.pone.0010105
- 发表时间:2010-04-16
- 期刊:
- 影响因子:3.7
- 作者:Lahat G;Zhu QS;Huang KL;Wang S;Bolshakov S;Liu J;Torres K;Langley RR;Lazar AJ;Hung MC;Lev D
- 通讯作者:Lev D
TNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis.
- DOI:10.1371/journal.pone.0016241
- 发表时间:2011-01-17
- 期刊:
- 影响因子:3.7
- 作者:Liu F;Hu X;Zimmerman M;Waller JL;Wu P;Hayes-Jordan A;Lev D;Liu K
- 通讯作者:Liu K
MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.
- DOI:10.1158/0008-5472.can-11-3027
- 发表时间:2012-04-01
- 期刊:
- 影响因子:11.2
- 作者:Zhang P;Bill K;Liu J;Young E;Peng T;Bolshakov S;Hoffman A;Song Y;Demicco EG;Terrada DL;Creighton CJ;Anderson ML;Lazar AJ;Calin GG;Pollock RE;Lev D
- 通讯作者:Lev D
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MENASHE BARELI其他文献
MENASHE BARELI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MENASHE BARELI', 18)}}的其他基金
AKT-Vimentin interaction; a potential role in soft tissue sarcoma progression and
AKT-波形蛋白相互作用;
- 批准号:
8249120 - 财政年份:2009
- 资助金额:
$ 29.14万 - 项目类别:
Biology and Therapeutic Targeting of the Epidermal Growth Factor Receptor in Blad
Blad 表皮生长因子受体的生物学和治疗靶向
- 批准号:
7729507 - 财政年份:2008
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
7895198 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
8327828 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
8728574 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
8380914 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
BIOLOGY AND THERAPEUTIC TARGETING OF IL-8 AND MUC18/MCAM
IL-8 和 MUC18/MCAM 的生物学和治疗靶向
- 批准号:
6993431 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
8541570 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Malignant melanoma: Regulation by AP-2 and PAR-1
恶性黑色素瘤:AP-2 和 PAR-1 的调节
- 批准号:
8259480 - 财政年份:1999
- 资助金额:
$ 29.14万 - 项目类别:
Malignant melanoma: Regulation by AP-2 and PAR-1
恶性黑色素瘤:AP-2 和 PAR-1 的调节
- 批准号:
8065375 - 财政年份:1999
- 资助金额:
$ 29.14万 - 项目类别:
相似国自然基金
签字注册会计师动态配置问题研究:基于临阵换师视角
- 批准号:72362023
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
全生命周期视域的会计师事务所分所一体化治理与审计风险控制研究
- 批准号:72372064
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
会计师事务所数字化能力构建:动机、经济后果及作用机制
- 批准号:72372028
- 批准年份:2023
- 资助金额:42.00 万元
- 项目类别:面上项目
会计师事务所薪酬激励机制:理论框架、激励效应检验与优化重构
- 批准号:72362001
- 批准年份:2023
- 资助金额:28.00 万元
- 项目类别:地区科学基金项目
环境治理目标下的公司财务、会计和审计行为研究
- 批准号:72332002
- 批准年份:2023
- 资助金额:165.00 万元
- 项目类别:重点项目
相似海外基金
GPCR Signaling in SCCHN: Integration with EGFR
SCCHN 中的 GPCR 信号转导:与 EGFR 整合
- 批准号:
8606299 - 财政年份:2014
- 资助金额:
$ 29.14万 - 项目类别:
Defining mechanisms of MEK1/2 inhibitor response in triple negative breast cancer
三阴性乳腺癌中 MEK1/2 抑制剂反应的定义机制
- 批准号:
8458188 - 财政年份:2012
- 资助金额:
$ 29.14万 - 项目类别:
Defining mechanisms of MEK1/2 inhibitor response in triple negative breast cancer
三阴性乳腺癌中 MEK1/2 抑制剂反应的定义机制
- 批准号:
8256291 - 财政年份:2012
- 资助金额:
$ 29.14万 - 项目类别: